Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β‐catenin pathway in NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Cell Proliferation"
DOI: 10.1111/cpr.12592
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI. Our study aimed to investigate… read more here.
Keywords: egfr tki; promotes erlotinib; erlotinib resistance; resistance ... See more keywords